Sanguine Media closes trading window from Oct 1 for Q2FY27 results
- Trading window closes from October 1, 2026, for Sanguine Media Limited
- Restriction covers promoters, directors, KMPs, and connected persons
- Window reopens 48 hours after Q2FY27 results declaration
- Compliance mandated under SEBI (Prohibition of Insider Trading) Regulations, 2015

*this image is generated using AI for illustrative purposes only.
Sanguine Media Limited closed its trading window on Thursday, October 1, 2026. This action precedes the declaration of unaudited financial results for the quarter ended September 30, 2026. The closure restricts insiders from dealing in the company's securities during this period.
The restriction applies to promoters, members of the promoter group, directors, key managerial personnel, and designated persons. It also extends to their immediate relatives and connected persons. The window will remain closed until 48 hours after the results are declared.
Regulatory compliance and scope
The company cited Clause 4(2) of Schedule B read with Regulation 9 of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. Additional references include SEBI Circular No. SEBI/HO/ISD/ISD-SEC-4/P/CIR/2022/107 dated August 5, 2022, and SEBI/HO/ISD/ISD-POD-2/P/CIR/2023/124 dated July 19, 2023.
All designated persons are advised not to enter into any transaction involving the securities of the company during the closure period. The company’s Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading in Securities by Designated Persons governs these restrictions.
Upcoming board meeting
The date for the board meeting to approve the financial results will be announced in due course. The filing was submitted to the BSE Limited by Aditya R Suryavanshi, Director, on September 28, 2026.
How might the upcoming unaudited financial results for Q2 FY2027 impact Sanguine Media's stock volatility once the trading window reopens?
What specific revenue drivers or cost efficiencies is the market expecting from Sanguine Media to justify potential valuation adjustments post-results?
Will the delayed announcement of the board meeting date signal any internal governance challenges or strategic delays in the company's reporting cycle?





























